Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics, Inc. (ANIK)
:ANIK
Holding ANIK?
Track your performance easily
ANIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.40 - $29.12
Previous CloseN/A
Volume22.29K
Average Volume (3M)78.21K
Market Cap
$235.35M
Enterprise Value$329.94M
Total Cash (Recent Filing)$124.76M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Feb 20, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.64
Shares Outstanding14,645,596
10 Day Avg. Volume69,097
30 Day Avg. Volume78,210
Standard Deviation0.11
R-Squared0.18
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)11.70
P/FCF Ratio18.40
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-14.61
Forecast
1Y Price Target
$25.00Price Target Upside55.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anika Therapeutics News
PremiumCompany Announcements
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
PremiumCompany Announcements
Anika Therapeutics Focuses on Core Growth Amid Restructuring
PremiumCompany Announcements
Anika Therapeutics Refocuses on Core Technology and Growth
Bulls Say, Bears Say
Bulls Say
Growth PotentialNew products are expected to primarily fuel the double-digit growth in the company's Joint Preservation & Restoration business.
Market LaunchThe upcoming U.S. commercial launches of Cingal and Hyalofast could have a significant financial impact.
Product DevelopmentPotential needle-mover products Cingal and Hyalofast have completed pivotal trials.
Bears Say
Financial OutlookManagement materially reduced its previous adjusted EBITDA guidance due to weakening OA pain volumes and softer pricing.
Regulatory IssuesCingal has been stalled from a regulatory perspective due to slow-moving conversations with the FDA.
RevenueAnika generated $38.8 million in revenue, which fell short of both the company's and the consensus estimates.
---
Ownership Overview
3.21% Insiders
14.89% Mutual Funds
<0.01% Other Institutional Investors
70.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANIK FAQ
What was Anika Therapeutics, Inc.’s price range in the past 12 months?
Anika Therapeutics, Inc. lowest stock price was $15.40 and its highest was $29.11 in the past 12 months.
What is Anika Therapeutics, Inc.’s market cap?
Anika Therapeutics, Inc.’s market cap is $235.35M.
When is Anika Therapeutics, Inc.’s upcoming earnings report date?
Anika Therapeutics, Inc.’s upcoming earnings report date is Feb 20, 2025 which is in 28 days.
How were Anika Therapeutics, Inc.’s earnings last quarter?
Anika Therapeutics, Inc. released its earnings results on Oct 31, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.34.
Is Anika Therapeutics, Inc. overvalued?
According to Wall Street analysts Anika Therapeutics, Inc.’s price is currently Undervalued.
Does Anika Therapeutics, Inc. pay dividends?
Anika Therapeutics, Inc. does not currently pay dividends.
What is Anika Therapeutics, Inc.’s EPS estimate?
Anika Therapeutics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Anika Therapeutics, Inc. have?
Anika Therapeutics, Inc. has 14,645,596 shares outstanding.
What happened to Anika Therapeutics, Inc.’s price movement after its last earnings report?
Anika Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -30.673%.
Which hedge fund is a major shareholder of Anika Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANIK
---
Anika Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (55.57% Upside)
$25.00 (55.57% Upside)
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.38%
12-Months-Change
Fundamentals
Return on Equity
-54.22%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a global, integrated joint preservation and regenerative therapies company focused on developing and commercializing innovative medical solutions that restore mobility and relieve pain for patients with degenerative orthopedic diseases and traumatic conditions. Operating primarily in the biotechnology and medical devices sectors, Anika offers a diverse portfolio of products including hyaluronic acid-based viscosupplements, joint preservation and restoration solutions, and regenerative therapies.
---
ANIK Company Deck
---
ANIK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strategic shifts focusing on HA-based products and international growth. However, significant challenges included the divestiture of underperforming assets and declining U.S. revenue. Despite these setbacks, growth in international markets and regulatory progress for key products provide a positive outlook.Read More>---
ANIK Stock 12 Month Forecast
Average Price Target
$25.00
▲(55.57% Upside)
Technical Analysis
Best Analysts Covering ANIK
1 Year
1 Year Success Rate
5/25 ratings generated profit
1 Year Average Return
-12.43%
reiterated a buy rating 3 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.43% per trade.
---